DE69131908D1 - Viruspartikel mit veraendertem wirtspektrum - Google Patents
Viruspartikel mit veraendertem wirtspektrumInfo
- Publication number
- DE69131908D1 DE69131908D1 DE69131908T DE69131908T DE69131908D1 DE 69131908 D1 DE69131908 D1 DE 69131908D1 DE 69131908 T DE69131908 T DE 69131908T DE 69131908 T DE69131908 T DE 69131908T DE 69131908 D1 DE69131908 D1 DE 69131908D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- incorporation
- disclosed
- economy
- changed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US658632 | 1976-02-17 | ||
US65863291A | 1991-02-19 | 1991-02-19 | |
PCT/US1991/005699 WO1992014829A1 (en) | 1991-02-19 | 1991-08-09 | Viral particles having altered host range |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69131908D1 true DE69131908D1 (de) | 2000-02-17 |
DE69131908T2 DE69131908T2 (de) | 2000-08-17 |
DE69131908T3 DE69131908T3 (de) | 2008-04-03 |
Family
ID=24642035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69131908T Expired - Lifetime DE69131908T3 (de) | 1991-02-19 | 1991-08-09 | Viruspartikel mit veraendertem wirtspektrum |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0572401B2 (de) |
JP (1) | JP3547129B2 (de) |
AT (1) | ATE188740T1 (de) |
CA (1) | CA2104396C (de) |
DE (1) | DE69131908T3 (de) |
WO (1) | WO1992014829A1 (de) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
AU3940293A (en) * | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
AU689755B2 (en) * | 1992-09-22 | 1998-04-09 | Biofocus Discovery Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
ATE263252T1 (de) * | 1992-11-09 | 2004-04-15 | Us Health | Erzielbare vektorenpartikel |
CA2158933A1 (en) * | 1993-09-03 | 1995-03-09 | John F. Warner | Methods of suppressing graft rejection |
WO1996009400A1 (en) * | 1994-09-19 | 1996-03-28 | Systemix, Inc. | Methods for genetically modifying hematopoietic stem cells |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
WO1997012968A1 (en) * | 1995-10-05 | 1997-04-10 | Chiron Corporation | Retroviral vectors pseudotyped with srv-3 envelope glycoprotein sequences |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
US5739018A (en) * | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
US6183993B1 (en) | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
WO1998012311A2 (en) | 1996-09-11 | 1998-03-26 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
JP2001508645A (ja) | 1996-09-11 | 2001-07-03 | ザ ジェネラル ホスピタル コーポレーション | 改変されたコート蛋白質を有する非哺乳動物dnaウイルス |
US6818209B1 (en) | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
US6300488B1 (en) | 1997-07-10 | 2001-10-09 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
CA2328491A1 (en) * | 1998-05-22 | 1999-12-02 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
AU5122499A (en) | 1998-07-27 | 2000-02-21 | Genentech Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
GB9907414D0 (en) | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
US7504253B2 (en) | 1999-06-11 | 2009-03-17 | The Burnham Institute For Medical Research | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof |
US7057015B1 (en) | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
WO2001068828A2 (en) | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
ES2307726T3 (es) | 2001-03-13 | 2008-12-01 | Novartis Ag | Construcciones de empaquetamiento lentiviral. |
CA2524619A1 (en) | 2005-11-22 | 2007-05-22 | Ottawa Health Research Institute | Novel stem cells, nucleotide sequences and proteins therefrom |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
ES2476798T3 (es) | 2006-11-27 | 2014-07-15 | Patrys Limited | Nueva diana de p�ptido glucosilado en células neopl�sicas |
NZ579050A (en) | 2007-02-06 | 2012-10-26 | Tai June Yoo | Treatment and prevention of neurodegenerative diseases using gene therapy |
EP2537522A1 (de) | 2007-08-02 | 2012-12-26 | California Stem Cell, Inc. | Neuronale Vorläuferzellen und Verfahren zur Ableitung und Reinigung neuronaler Vorläuferzellen aus embryonischen Stammzellen |
WO2009049351A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Construct system and uses therefor |
AU2008323853B8 (en) | 2007-11-08 | 2014-07-24 | Beth Israel Deaconess Medical Center | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28 |
US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
CA2715373C (en) | 2008-02-15 | 2019-11-05 | Tufts University | A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration |
ES2618851T3 (es) | 2008-06-18 | 2017-06-22 | Oxford Biomedica (Uk) Limited | Purificación de vectores retrovirales |
US8999919B2 (en) | 2008-10-22 | 2015-04-07 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between CFTR and CAL |
US8211487B2 (en) | 2008-11-26 | 2012-07-03 | Srinivasan Damodaran | Inhibition of ice crystal growth |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
HUE025966T2 (en) | 2009-04-27 | 2016-05-30 | Kyowa Hakko Kirin Co Ltd | Anti-IL-3RA antibody for use in the treatment of blood cancer |
US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
CA2843684A1 (en) | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein |
CA2848765A1 (en) | 2011-09-15 | 2013-03-21 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Immunotherapy and diagnosis of mucormycosis using coth |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
WO2014124334A2 (en) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
WO2014197535A1 (en) | 2013-06-04 | 2014-12-11 | Virginia Commonwealth University | Recombinant cancer therapeutic cytokine |
EP3004357A4 (de) | 2013-06-04 | 2017-01-11 | The Johns Hopkins University | Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin |
US9701985B2 (en) | 2013-06-04 | 2017-07-11 | Virginia Commonwealth University | mda-9/syntenin promoter to image and treat metastatic cancer cells |
EP3003022B1 (de) | 2013-06-04 | 2017-11-22 | Virginia Commonwealth University | Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika |
EP3003393A4 (de) | 2013-06-04 | 2017-01-11 | The Johns Hopkins University | Dreiteilige theranostische krebs-nukleinsäurekonstrukte |
US20160152952A1 (en) | 2013-06-25 | 2016-06-02 | Temple University-Of The Commonwealth System Of Higher Education | Cortical Bone-Derived Stem Cells |
AU2015308773B2 (en) | 2014-08-28 | 2021-03-25 | Tufts University | Compositions, methods and kits for treating complement related disorders |
US9901639B2 (en) | 2015-02-13 | 2018-02-27 | Temple University—Of the Commonwealth System of Higher Education | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease |
CN105372433A (zh) * | 2015-08-21 | 2016-03-02 | 深圳出入境检验检疫局动植物检验检疫技术中心 | 一种水泡性口炎病毒抗体快速检测试纸条 |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
JP7110108B2 (ja) | 2015-12-09 | 2022-08-01 | ジンガン メディスン(オーストラリア) プロプライアタリー リミティド | 治療用免疫調節組成物 |
EP3299460A1 (de) | 2016-09-26 | 2018-03-28 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Neuartige verbindungen und verfahren zur modulation der ubiquitinierung |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
CA3090997A1 (en) | 2018-02-12 | 2019-08-15 | Trustees Of Tufts College | Cd59 for inhibiting inflammasome activation |
KR20220061977A (ko) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
WO2023089564A1 (en) | 2021-11-19 | 2023-05-25 | Janssen Biotech, Inc. | Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
FR2619012B1 (fr) * | 1987-08-07 | 1989-12-22 | Pasteur Institut | Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus |
IL92298A (en) * | 1988-11-14 | 2001-04-30 | Us Secretary U S Dept Of Comme | Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
WO1990015141A2 (en) * | 1989-06-01 | 1990-12-13 | Applied Biotechnology, Inc. | Self-assembled, defective, non-self-propagating viral particles |
WO1991002508A1 (de) * | 1989-08-21 | 1991-03-07 | Brackmann Hans Peter | Tragbare datenerfassungsvorrichtung therapierelevanter ereignisse |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
-
1991
- 1991-08-09 JP JP51451891A patent/JP3547129B2/ja not_active Expired - Lifetime
- 1991-08-09 WO PCT/US1991/005699 patent/WO1992014829A1/en active IP Right Grant
- 1991-08-09 EP EP91915104A patent/EP0572401B2/de not_active Expired - Lifetime
- 1991-08-09 CA CA002104396A patent/CA2104396C/en not_active Expired - Lifetime
- 1991-08-09 AT AT91915104T patent/ATE188740T1/de not_active IP Right Cessation
- 1991-08-09 DE DE69131908T patent/DE69131908T3/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1992014829A1 (en) | 1992-09-03 |
EP0572401A1 (de) | 1993-12-08 |
JP3547129B2 (ja) | 2004-07-28 |
CA2104396C (en) | 2000-10-10 |
AU663470B2 (en) | 1995-10-12 |
EP0572401B2 (de) | 2007-11-07 |
DE69131908T2 (de) | 2000-08-17 |
EP0572401B1 (de) | 2000-01-12 |
JPH06504905A (ja) | 1994-06-09 |
AU8430291A (en) | 1992-09-15 |
DE69131908T3 (de) | 2008-04-03 |
ATE188740T1 (de) | 2000-01-15 |
CA2104396A1 (en) | 1992-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69131908T2 (de) | Viruspartikel mit veraendertem wirtspektrum | |
DE69636878D1 (de) | Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie | |
IL89701A0 (en) | Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same | |
ZA925735B (en) | Stable recombinant yeasts useful for the production of recombinant proteins,their preparation and their use | |
NO871785D0 (no) | Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse. | |
DK0561890T3 (da) | DNA ekspressionssystemer baseret på alphavira | |
ATE316571T1 (de) | Purifikation von viruspräparaten | |
ATE114476T1 (de) | Tierische zelle mit darin eingeführtem antigenem protein. | |
WO1991002805A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
DK79887A (da) | Vektor til ekspression af gamma-interferon i pattedyrceller, fremgangsmaade til fremstilling deraf, det vundne produkt samt farmaceutisk praeparat indeholdende gamma-interferonet | |
KR900700592A (ko) | 용해성 티-4 유도체 | |
DE69921435D1 (de) | Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren | |
HU9300187D0 (en) | Applications of recombinant dna of synoythioma virus proteines, vaccines, antibodies and transformed cells of cattle's breathing organs | |
GR3024137T3 (en) | A modified transcription control unit and uses thereof | |
DE69022233D1 (de) | Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen. | |
DE69636456D1 (de) | In-vitro verpackung von adeno-assozierten virus dns | |
Bosworth et al. | Evaluation of age-related effects on the antiviral activity of interferon and induction of 2-5A synthetase in testicular cell cultures derived from swine of various ages | |
JPS5545618A (en) | Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte | |
ES2175184T3 (es) | Virus que expresan proteinas toxicas y leneas celulares productoras. | |
TW251319B (en) | A preparation process for Hepatitis B surface antigen granule carrying Hepatitis delta virus antigen | |
Snoddy | Interferon regulated expression of a multigene complex on mouse chromosome 1 | |
ITRM930551A0 (it) | Procedimento per la propagazione del virus dell'epatite c in colture cellulari animali non linfoblastoidi e relativo prodotto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: OXFORD BIOMEDICA (UK) LTD., OXFORD, GB Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, O, US |